Oncology Venture ready for turning Novartis candidate into precision medicine

Danish biotech firm Oncology Venture has fine-tuned its DRP technology to become better at predicting which patients will benefit from treatment with Novartis' candidate dovitinib against cancer in the kidneys and uterus.

Photo: Oncology Venture, PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles